News

In a new study entitled “Dopaminergic Modulation of Decision Making and Subjective Well-Being”, published in the Journal of Neuroscience, researchers show that decisions on risk-taking may be influenced by a boost in the levels of the neurotransmitter dopamine. These findings are in line with previous reports that…

Progressive loss of neurons in the brains of Parkinson’s patients is a slow yet inexorable process, and so far, there are no drugs that can halt this insidious process. However, teams of researchers at the Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg have now…

Researchers at the University of Alabama at Birmingham (UAB) and Pfizer Inc. recently reported encouraging findings on a new inhibitor drug that can reduce neurodegeneration in animal models of Parkinson’s disease. The study was published in The Journal of Biological Chemistry and is entitled “…

Rehovot, Israel based Pharma Two B Ltd. is reportedly mulling issuance of an IPO after announcing successful results in the company’s Phase IIb pivotal study of P2B001 for treatment of early stage Parkinson’s Disease (PD) which is boosting the company’s confidence in taking its quest for financing to…

Many late-stage Parkinson’s disease patients have a high risk of suffering dangerous, sometimes fatal, falls. A major reason for increased propensity for falling is the disabling Parkinson’s symptom referred to as “Freezing of Gait” (FoG) — brief episodes of inability to step forward typically occurring during initiation of a step or…

A collaboration between researchers from the University of Leicester, the University of California Los Angeles and Tel-Aviv University identified neurons responsible for the creation of memories on everyday episodes. The study entitled “Rapid Encoding of New Memories by Individual Neurons in the Human Brain” appeared  July 1, 2015…

Tekes, the Finnish Funding Agency for Innovation, has granted a 2,903,000 EUR R&D loan to Herantis Pharma Plc. — a Finnish a pharmaceutical company that specializes in new drug research and development — to support its clinical study of Cerebral Dopamine Neurotrophic Factor (CDNF), a proprietary neuroprotective and…

The National Parkinson Foundation (NPF) has raised almost $1 million through the Moving Day, A Walk for Parkinson’s initiative that took place this spring. The funding will be invested in mission services in Washington, D.C., Tampa, and the Bay Areain CA, designed to improve the lives of patients…

Physician and scientist Mahlon DeLong, MD, was recognized for his achievements in the treatment of Parkinson’s disease with the 2015 Taubman Prize for Excellence in Translational Medical Science. The University of Michigan’s A. Alfred Taubman Medical Research Institute announced it was awarding DeLong for his contributions to improve the lives…

Researchers at Aarhus University and Aarhus University Hospital in Denmark recently reported new evidence that Parkinson’s disease development may actually start in the gut. The study entitled “Vagotomy and subsequent risk of Parkinson’s disease” was published in the journal Annals of Neurology.